Although promising data were published, the clinical program of Andecaliximab (a chimeric recombinant IgG4 against MMP-9, formerly named GS-5745, Gilead Sciences) was stopped in IBD for futility reasons. The gene discussed is MMP9; the disease is inflammatory bowel disease.